GSK has announced plans for the divestiture of its 2.9% stake in consumer healthcare company Haleon for £885.6m ($1.07bn).

The offloading comprises 270 million shares of Haleon held by GSK.

In July 2022, GSK concluded the spin-off of its consumer healthcare business to create Haleon, an independent listed company. 

The original consumer healthcare business was a joint venture between GSK and Pfizer in which the two companies held 68% and 32% stakes respectively.

Following the spin-off, GSK retained a 12.94% stake in Haleon.

In May 2023, GSK then offloaded 240 million ordinary shares in Haleon for $1bn.

The disposal reduced the stake held by GSK in Haleon to 10.3%.

GSK will execute the latest stake sale by divesting the ordinary shares in Haleon to institutional investors.

In a stock exchange filing, GSK stated: “The offer price will be determined by means of an accelerated bookbuild offering process which is to start immediately.”

GSK also signed a secondary block trade agreement to appoint Bank of America Securities and Citigroup Global Markets as joint global co-ordinators of the offering.

GSK and Pfizer have agreed that the companies will not divest any shares in Haleon for 60 days following the date of the settlement.

Pfizer announced plans to offload its 32% stake in Haleon in June 2022.